- Home
- BIIB vs ASX Comparison
BIIB vs ASX Comparison
Compare BIIB & ASX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ASX
- Stock Information
- Founded
- BIIB 1978
- ASX 1984
- Country
- BIIB United States
- ASX Taiwan
- Employees
- BIIB N/A
- ASX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ASX Semiconductors
- Sector
- BIIB Health Care
- ASX Technology
- Exchange
- BIIB Nasdaq
- ASX Nasdaq
- Market Cap
- BIIB 25.1B
- ASX 22.5B
- IPO Year
- BIIB 1991
- ASX 1995
- Fundamental
- Price
- BIIB $164.23
- ASX $10.01
- Analyst Decision
- BIIB Buy
- ASX Strong Buy
- Analyst Count
- BIIB 25
- ASX 1
- Target Price
- BIIB $258.57
- ASX N/A
- AVG Volume (30 Days)
- BIIB 1.7M
- ASX 6.6M
- Earning Date
- BIIB 10-30-2024
- ASX 10-31-2024
- Dividend Yield
- BIIB N/A
- ASX 3.21%
- EPS Growth
- BIIB 10.05
- ASX N/A
- EPS
- BIIB 11.06
- ASX 0.23
- Revenue
- BIIB $9,607,500,000.00
- ASX $18,693,593,707.00
- Revenue This Year
- BIIB N/A
- ASX $6.13
- Revenue Next Year
- BIIB N/A
- ASX $14.78
- P/E Ratio
- BIIB $14.85
- ASX $20.16
- Revenue Growth
- BIIB N/A
- ASX N/A
- 52 Week Low
- BIIB $153.62
- ASX $8.10
- 52 Week High
- BIIB $268.30
- ASX $12.86
- Technical
- Relative Strength Index (RSI)
- BIIB 42.84
- ASX 54.33
- Support Level
- BIIB $158.44
- ASX $9.31
- Resistance Level
- BIIB $160.63
- ASX $9.99
- Average True Range (ATR)
- BIIB 4.14
- ASX 0.21
- MACD
- BIIB 0.94
- ASX 0.02
- Stochastic Oscillator
- BIIB 47.71
- ASX 94.59
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ASX ASE Technology Holding Co. Ltd. (each representing Two)
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, Electronic Manufacturing Services contribute the maximum revenue. The packaging segment involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufactures, and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.